NTRA241220C125000
- 42.00
- 0.000.00%
Natera Newsroom
Insider Sale: EXECUTIVE CHAIRMAN of $NTRA (NTRA) Sells 400 Shares
Express News | Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $200
Piper Sandler Sticks to Their Buy Rating for Natera (NTRA)
Trade Alert: Independent Director Of Natera Gail Marcus Has Sold Stock
Express News | Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Express News | Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Express News | Natera Inc - to Ask Court to Overturn Jury Decision in Guardant Case
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Natera Issues Statement on Guardant Health Litigation
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
United States Non-Invasive Prenatal Testing Market Report 2025-2033: Illumina, Roche, and Natera, Which Have Established Themselves as Leaders Through Robust Research and Development
Insider Sale: Director at $NTRA (NTRA) Sells 2,100 Shares
Natera Announces Publication of Over 100 Peer-Reviewed Papers on SignateraTM
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Trump Media Saw the Largest Increase in Short Interest in October
UBS Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $209
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas